Expression of the insulin-like growth factor-II/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy
Open accessThe DOI matches its Crossref record.
Abstract
The insulin like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptor has been detected in many cells and tissues. In the rat, there is a dramatic developmental regulation of IGF-II/M6P receptor expression, the receptor being high in fetal and neonatal tissues and declining thereafter. We have systematically studied the expression of the human IGF-II/M6P receptor protein in tissues from 10 human fetuses and infants (age 23 weeks gestation to 24 months postnatal). We have asked 1) whether there is differential expression among different organs, and 2) whether or not the human IGF-II/M6P receptor is developmentally regulated from 23 weeks gestation to 24 months postnatal. Protein was extracted from human tissues using a buffer containing 2% sodium dodecyl sulfate and 2% Triton X-100. Aliquots of the protein extracts were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting using an anti-IGF-II/M6P receptor antiserum (no. 66416) and 125I-protein A or an immunoperoxidase stain. IGF-II/M6P receptor immunoreactivity was detected in all tissues studied with the highest amount of receptor being expressed in heart, thymus, and kidney and the lowest receptor content being measured in brain and muscle. The receptor content in ovary, testis, lung, and spleen was intermediate. The apparent molecular weight of the IGF-II/M6P receptor (220,000 kilos without reduction of disulfide bonds) varied among the different tissues: in brain the receptor was of lower molecular weight than in other organs. Immunoquantitation experiments employing 125I-protein A and protein extracts from human kidney at different ages revealed a small, albeit not significant, difference of the receptor content between fetal and postnatal tissues: as in other species, larger amounts of receptor seemed to be present in fetal than in postnatal organs. In addition, no significant difference of the receptor content between human fetal liver and early postnatal liver was measured employing 125I-protein A-immunoquantitation in three fetal and five postnatal liver tissue samples. The distribution of IGF-binding protein (IGEBP) species, another abundant and major class of IGF binding principles, was also measured in human fetal and early postnatal lung, liver, kidney, muscle, and brain using Western ligand blotting with 125I-IGF-II: as with IGF-II/M6P receptor immunoreactivity there was differential expression of the different classes of IGFBPs in the various organs.(ABSTRACT TRUNCATED AT 400 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Amalfitano, A., Bengur, A. R., Morse, R. P., Majure, J. M., Case, L. E., Veerling, D. L., Mackey, J., Kishnani, P., Smith, W., McVie-Wylie, A., et al. (2001) · Genetics in Medicine · doi:10.1038/gim200127 · Cited by 347
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
Spampanato, C., Feeney, E., Li, L., Cardone, M., Lim, J., Annunziata, F., Zare, H., Polishchuk, R., Puertollano, R., Parenti, G., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202176 · Cited by 341
“…response to the recombinant enzyme in cross-reactive immunologic material (CRIM)-negative patients and the presence of large areas of autophagic build-up alongside expanded lysosomes (Banugaria et al, 2011; Funk et al, 1992; Kishnani et al, 2010; Koeberl et al, 2012; Raben et al, 2002, 2010, 2012).”
Gnessi, L., Fabbri, A., & Spera, G. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.4.0310 · Cited by 306
Neuroendocrine Control of Thymus Physiology*
Savino, W., & Dardenne, M. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.4.0402 · Cited by 299
Reindl, K. M., & Sheridan, M. A. (2012) · Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2012.08.003 · Cited by 286
Kishnani, P. S., Nicolino, M., Voit, T., Rogers, R. C., Tsai, A. C.-H., Waterson, J., Herman, G. E., Amalfitano, A., Thurberg, B. L., Richards, S., et al. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.02.035 · Cited by 282
Enzyme replacement therapy in the mouse model of Pompe disease
Raben, N., Danon, M., Gilbert, A. L., Dwivedi, S., Collins, B., Thurberg, B. L., Mattaliano, R. J., Nagaraju, K., & Plotz, P. H. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.022 · Cited by 217
Gene therapy for metachromatic leukodystrophy
Rosenberg, J. B., Kaminsky, S. M., Aubourg, P., Crystal, R. G., & Sondhi, D. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23792 · Cited by 91
“…manifestations of several lysosomal disorders by taking advantage of the ability of the cell to take up infused enzyme via the cation-independent mannose-6phosphate (M6P) receptors present on the surface of virtually all cells (Funk et al., 1992; Ghosh et al., 2003; Willingham et al., 1981).”
BackgroundTakeda, T., Komatsu, M., Chiwaki, F., Komatsuzaki, R., Nakamura, K., Tsuji, K., Kobayashi, Y., Tominaga, E., Ono, M., Banno, K., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2117-9 · Cited by 60
Rosenberg, J. B., Sondhi, D., Rubin, D. G., Monette, S., Chen, A., Cram, S., De, B. P., Kaminsky, S. M., Sevin, C., Aubourg, P., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.239 · Cited by 58
“The CNS manifestations of MLD are ideal for a CNS gene therapy approach because the ARSA enzyme is secreted into the extracellular matrix and incorporated into neighboring and distant cells via the ubiquitous cell surface, mannose 6phosphate (M6P) receptor (Willingham et al., 1981; Funk et al., 1992; Ghosh et al., 200…”
BackgroundInfluentialShort-term, high dose enzyme replacement therapy in sialidosis mice
Wang, D., Bonten, E. J., Yogalingam, G., Mann, L., & d’Azzo, A. (2005) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2005.03.007 · Cited by 50
Rosenberg, J. B., Chen, A., De, B. P., Dyke, J. P., Ballon, D. J., Monette, S., Ricart Arbona, R. J., Kaminsky, S. M., Crystal, R. G., & Sondhi, D. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.269 · Cited by 41
Metadata
- Authors
- Funk, B.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1992-08-01
- Volume
- 75
- Issue
- 2
- Pages
- 424-431
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2158681568
- Cited by
- 98
- References
- 0
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.